Investor Presentaiton
LAG-3 Cluster: IBI-110 (LAG-3 mAb) and IBI-323 (PD-L1/LAG-3
Bispecific Antibody)
IBI-110 Clinical Highlights
Promising preliminary results in Phase 1a and 1b
Well tolerated. No DLT observed
Good safety profile. TRAE mostly grade 1-2.
Anti-tumor activity observed in both monotherapy and combo
therapy in Phase 1
Plan to release data in 2021
•
•
IBI-323 Preclinical Highlights
Dual blockade of LAG-3 and PD-L1. Blocking LAG-3 can also inhibit the
negative regulatory effect of Treg's, with a stronger and longer-lasting T-
cell activity potential than single target.
With bridging effect as bispecific antibody, tumor cells expressing PD-L1
can be closer to T cells expressing LAG-3, thus forming a stable TCR:MHC
immune synapse that further activates T cells.
IBI-110 Development Program Overview
IBI-323 Development Program Overview
Clinical
Completed patient enrolment for Phase 1a trial in 2020
Clinical
•
IND application approved for IBI-323 in advanced cancer in the
second half of 2020.
progress
•
Completed patient enrolment for Phase 1b trial in Jan 2021
progress
Continue the development of IBI-110 in 2021
2021 plan
2021 plan
• Get PoC data in 2021
Plan to start the patient enrolment of Phase 1 clinical study of
IBI-323 in 2021.
•
Publish the Phase 1 data of IBI-110 at medical conference in 2021
Leading and highly differentiated position in LAG-3 with IBI-110 (LAG-3 mAb) moving fast to get PoC in 2021, and IBI-323 (PD-L1/LAG-3) in
Phase 1 with novel biological mechanism and potential strong synergy.
Innovent
Confidential
Copyright©2021 Innovent Biologics
26
26View entire presentation